Brit Mollenhauer, MD, received her medical degree from the University Medical Center in Goettingen, Germany in 2000 and stayed there for her residency training in neurology until 2005. From 2005 to 2007, Dr. Mollenhauer visited Harvard Medical School in Boston, Massachusetts as a postdoctoral fellow. At Harvard, she worked on developing biomarkers -- objective measures of disease -- and studied alpha-synuclein, a sticky protein that clumps in the brains of people with Parkinson's disease (PD), in cerebrospinal fluid. Since June 2007, she has been an assistant professor of neurology at University Medical Center Goettingen and Movement Disorder Paracelsus-Elena-Klinik, Kassel. Since 2019 she has been an Associate Professor in the Department of Neurology at University Medical Center Goettingen.
Given Dr. Mollenhauer's background in neurochemistry, her research team focuses on the detection of biomarkers in human bodily fluids and the development of experimental techniques for improved diagnosis of movement disorders. At Movement Disorder Paracelsus-Elena-Klinik, Kassel, she conducts clinical research involving volunteers with isolated REM sleep behavior disorder (RBD) and newly diagnosed Parkinson's. Dr. Mollenhauer has published more than 125 original articles and received a Web of Science Award 2019 and in 2020 as one of the highly cited researchers worldwide. She is a member of the executive steering committee and co-chair of the Bioanalytics Core of the Parkinson Progression Markers Initiative (PPMI), The Michael J. Fox Foundation's landmark clinical study to find biomarkers -- disease indicators that are critical missing links in the search for better Parkinson's treatments. She is also co-PI of the Systemic Synuclein Sampling Study (S4) and joined the Executive Scientific Advisory Board of MJFF in 2020.